Search tips
Search criteria 


Logo of omanjophthalHomeCurrent issueInstructionsSubmit article
Oman J Ophthalmol. 2010 May-Aug; 3(2): 99–100.
PMCID: PMC3003863

Combined photodynamic therapy and intravitreal ranibizumab as treatment for extrafoveal choroidal neovascularization associated with age-related macular degeneration


We report the efficacy of combination therapy using photodynamic therapy (PDT) and intravitreal ranibizumab for extrafoveal choroidal neovascular membrane (CNVM) associated with age-related macular degeneration (ARMD) in an Indian patient.

A 74-year-old man presented with decreased vision in the right eye (OD) since two years. He was a known diabetic on treatment. He was on anti-glaucoma medication for both the eyes (OU). On examination his best corrected visual acuity was 20/80 OD and 20/2000 in the left eye (OS). Biomicroscopic evaluation of the anterior segment of both the eyes was unremarkable except for aphakia. Intraocular pressures were 12 mmHg OU. Fundus examination OD revealed a subretinal membrane with retinal pigment epithelium alteration. The optic disc showed signs of glaucomatous cupping (cup-disc ratio 0.6). Fundoscopy OS showed macular scarring with glaucomatous cupping (cup-disc ratio 0.6). Fundus fluorescein angiography (FFA) showed typical lacy leakage suggestive of classic CNVM OD. Optical coherence tomography (OCT) showed retinal thickening with subretinal fluid [Figure 1a]. Considering the location of the CNVM and the single-eyed status of the patient, laser photocoagulation was thought to be best avoided. The patient underwent PDT (5.3 ml of Verteporfin in 24.3 ml of D5W, laser spot size of 2.6mm, using diode laser (wavelength 689nm) as per standard protocol followed by intravitreal ranibizumab (0.5 mg), two days later in the right eye. No treatment-related adverse effect was noted. At four weeks follow-up, visual acuity improved to 20/40. Clinical examination revealed absence of subretinal fluid but persistence of increased retinal thickness on OCT [Figure 1b]. A second intravitreal ranibizumab injection was performed. At eight weeks follow-up, visual acuity improved to 20/30. Clinical examination revealed a scarred CNVM [Figure 1c]. The fundus remained stable and visual acuity was maintained at the sixth month follow-up.

Figure 1
Serial Optical Coherence Tomography (OCT) (a-c) showing decrease in retinal thickness, resolution of subretinal fluid with restoration of normal foveal contour

Combined treatment using PDT and bevacizumab has been shown to be effective in improving visual acuity and decreasing retreatment rates in choroidal neovascularization (CNV) associated with ARMD.[1] The combined regime is postulated to have a beneficial synergistic effect that reduces the need for cyclic injections.[1,2]

Heier et al. reported greater efficacy with combination therapy using ranibizumab and PDT when compared to therapy with PDT alone.[3] VEGF inhibition alone could prevent neovascularization at an early developmental stage. However, once neovascular beds are established they are unlikely to regress with anti-VEGF therapy alone.[3]

Combination therapy treatment using PDT and ranibizumab as the first-line management in treatment of CNVM in one-eyed patients is a safe and effective treatment option, leading to a permanent cure. Combination therapy has a beneficial effect of reduced number of injections on reducing the attendant cumulative risk of endophthalmitis with each additional injection.


1. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol. 2006;141:149–56. [PubMed]
2. Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2006;26:988–93. [PubMed]
3. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS Study. Arch Ophthalmol. 2006;124:1532–42. [PubMed]

Articles from Oman Journal of Ophthalmology are provided here courtesy of Medknow Publications